{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","upperLimit":"42.6","value":"27.66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"The ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1), where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeters (mm) in the short axis, PR=At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Primary Analysis Population comprised of participants who received 3 or 4 prior lines of therapy (LOT), had homologous recombination deficiency positive (HRDpos) tumors, had platinum-sensitive disease, and were poly(adenosine 5'-diphosphate \\[ADP\\]-ribose) polymerase inhibitors (PARPi) naïve.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"OG000","title":"Niraparib 300 mg"}],"paramType":"NUMBER","populationDescription":"Primary Analysis Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}